A pilot study to assess oxidative and inflammatory markers as early indicator for response to chemotherapy in non-small cell lung cancer.

Diksha DikshaPooja GuptaPrabhat Singh MalikAnant Mohan

Published in: Journal of clinical pharmacy and therapeutics (2019)

Although the levels of oxidative and inflammatory markers varied following chemotherapy, trend indicates that IL-6 may be a potential marker of treatment response in NSCLC patients.

Keyphrases

end stage renal disease
ejection fraction
small cell lung cancer
locally advanced
chronic kidney disease
prognostic factors
squamous cell carcinoma
advanced non small cell lung cancer
risk assessment
rectal cancer
climate change